EGFR family: structure physiology signalling and therapeutic targets

Area of Science:

• Molecular Biology
• Cell Signaling
• Oncology

Background:

• The Epidermal Growth Factor Receptor (EGFR) family comprises four members: EGFR, erbB2, erbB3, and erbB4.
• These receptors form ligand-activated oligomers, functioning as a tyrosine kinase scaffold to regulate intracellular processes.
• Proper function of EGFR family members is essential, as deficiencies lead to severe developmental defects.

Purpose of the Study:

• To review the structure and function of the EGFR family.
• To highlight the role of EGFR and erbB2 in cancer.
• To discuss the therapeutic potential of targeting EGFR family signaling in oncology.

Main Methods:

• Literature review of EGFR family signaling pathways.
• Analysis of gene expression and mutation data in cancer.
• Examination of preclinical and clinical data for EGFR/erbB2 inhibitors.

Main Results:

• EGFR family members dimerize to activate signaling pathways.
• Absence of any EGFR family member results in embryonic lethality.
• EGFR and erbB2 are frequently dysregulated in various cancers.
• Targeted therapies against EGFR and erbB2 have demonstrated clinical efficacy.

Conclusions:

• The EGFR family is critical for normal development and cellular function.
• Dysregulation of EGFR and erbB2 signaling is a hallmark of many cancers.
• Inhibitors targeting EGFR and erbB2 represent effective therapeutic strategies for cancer treatment.